GlassScriptPhysician profile
Claire Schack
NPI 1003468968
$5,754.50
in general payments reported to CMS, 2019-2025
39 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $948 · 2022: $493 · 2023: $2,416 · 2024: $861 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,003 · Travel and Lodging: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.11 |
| Travel and Lodging | $1,310.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,635.03 | 2023 | |
| Abbvie INC. | $1,100.59 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $372.01 | 2023-2025 | Caplyta |
| Glaxosmithkline, LLC. | $315.56 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $258.17 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $198.92 | 2021-2025 | |
| Lilly USA, LLC | $163.33 | 2021-2024 | Mounjaro |
| Axsome Therapeutics, INC. | $158.76 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $123.98 | 2023-2024 | Spravato |
| Seqirus USA INC | $114.79 | 2024 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $108.75 | 2021-2025 | |
| Indivior INC. | $97.09 | 2023-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $95.46 | 2024-2025 | Glassia, Aralast |
| Otsuka America Pharmaceutical, INC. | $92.21 | 2021-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.50 | 2021-2025 | Xifaxan, Trulance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $87.50 | 2024-2025 | Fanapt |
| Grifols USA, LLC | $85.78 | 2021-2025 | Prolastin-C Liquid |
| Alkermes, INC. | $71.95 | 2023 | Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.99 | 2021-2023 | Jardiance |
| Astellas Pharma US INC | $50.97 | 2024 | Veozah |
| Novo Nordisk INC | $45.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $42.40 | 2021 | |
| Merck Sharp & Dohme LLC | $41.08 | 2021-2022 | |
| Mylan Specialty L.P. | $35.77 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $35.51 | 2024-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $28.30 | 2022-2023 | Evenity, Prolia |
| Dexcom, INC. | $25.41 | 2021 | |
| Almatica Pharma LLC | $23.92 | 2023 | Gralise, Loreev Xr |
| Edwards Lifesciences Corporation | $22.67 | 2025 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $22.51 | 2022 | |
| Biomerieux INC | $19.74 | 2025 | Biofire Spotfire Control Station |
| Gilead Sciences, INC. | $19.02 | 2023 | |
| Corcept Therapeutics | $18.82 | 2024 | Korlym |
| Exact Sciences Corporation | $15.96 | 2024 | Cologuard Collection Kit |
| Lundbeck LLC | $15.55 | 2023 | Rexulti |
| Corium, LLC | $12.85 | 2023 | Azstarys |
| Abbott Laboratories | $12.37 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.06 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Schack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.